Melissa Schutten
exeutive director Gilead Sciences
Melissa Schutten is a Veterinary Pathologist at Gilead, where she works in Nonclinical Safety Assessment to support the development of oncology therapeutics. In her current role, she focuses on evaluating the safety of complex modalities, including ADCs. Melissa brings more than a decade of industry experience, having held scientific roles at Genentech from 2010 to 2021, followed by positions at Seagen (2021–2025) and Pfizer. Across these roles, her work has been heavily centered on the nonclinical safety assessment of ADCs and other oncology molecules.
Seminars
Even with 2026 seeing ADCs continue to rival oncology standard of care performance, translation of ADC toxicity profiles to the clinic remains the largest hurdle to widen ADC therapeutic index and accomplish widespread impact for patients in need.
Led by long-standing ADC toxicity experts, join your peers to understand ADC class effect toxicities and best leverage preclinical tools and historical learnings to effectively characterize safety profiles and predict ADC tolerability in the clinic.
Workshop highlights include:
- Discussing ADC class effect toxicities observed in the clinic across ocular toxicity, ILD, neutropenia and beyond
- Delving into deployment and utilization of in vivo and in vitro models to improve prediction of clinical toxicity profiles
- Breaking down lessons learned from successful and failed historical ADC translation to inform design, engineering and characterization of better ADCs with wider therapeutic index
